Latest Pharma Insights
Growth Drug In Infant Supplements Adds To US Regulators’ Children’s Health Product Concerns
When FDA warned Agebox about selling iKids-Growth IGF-1 Support supplements as unapproved drugs, agency along with CDC had for around a month been investigating outbreak of infant botulism linked to ByHeart formula.
HBW Insight - January 27, 2026
When FDA warned Agebox about selling iKids-Growth IGF-1 Support supplements as unapproved drugs, agency along with CDC had for around a month been investigating outbreak of infant botulism linked to ByHeart formula.
HBW Insight - January 27, 2026
Genmab Stops Recruiting Patients In Trial Of ProfoundBio ADC GEN1286
The Phase I/II study’s trial page was updated to say it was no longer recruiting patients after recruiting only 23 of the originally planned 260.
Scrip - January 26, 2026
The Phase I/II study’s trial page was updated to say it was no longer recruiting patients after recruiting only 23 of the originally planned 260.
Scrip - January 26, 2026
BioNTech Plans For Commercial Entry Into Oncology
The company is getting ready for multiple cancer drug launches, potentially including anti-PD-L1/VEGF pumitamig. Chief commercial officer Annemarie Hanekamp spoke to Scrip.
Scrip - January 26, 2026
The company is getting ready for multiple cancer drug launches, potentially including anti-PD-L1/VEGF pumitamig. Chief commercial officer Annemarie Hanekamp spoke to Scrip.
Scrip - January 26, 2026
Ousted CytoDyn CEO Pourhassan Sentenced To 30 Months For Securities Fraud
The CytoDyn board of directors fired Nader Pourhassan in early 2022 as the company faced US FDA scrutiny over his comments about HIV and COVID-19 candidate leronlimab and as investors sued the firm.
Scrip - January 26, 2026
The CytoDyn board of directors fired Nader Pourhassan in early 2022 as the company faced US FDA scrutiny over his comments about HIV and COVID-19 candidate leronlimab and as investors sued the firm.
Scrip - January 26, 2026
After Another Difficult Year, UK Biotech Hopes For A Stronger 2026
Companies requiring follow-on financing were particularly hit in 2025, but the first signs of ‘pension power’ has given the UK sector hope of more investment.
Scrip - January 26, 2026
Companies requiring follow-on financing were particularly hit in 2025, but the first signs of ‘pension power’ has given the UK sector hope of more investment.
Scrip - January 26, 2026
Argenx Is A Standout In Biotech; Can Its High-Powered Growth Continue?
The company’s chief operating officer and next CEO Karen Massey talked with Scrip about the rise of Vyvgart and how the Dutch biotech is planning for the next phase of growth.
Scrip - January 26, 2026
The company’s chief operating officer and next CEO Karen Massey talked with Scrip about the rise of Vyvgart and how the Dutch biotech is planning for the next phase of growth.
Scrip - January 26, 2026
Stock Watch: J&J’s Strong Earnings Go Unrewarded
Despite group sales growth and its pharmaceutical division revenue weathering a big loss of exclusivity, J&J experienced stock price weakness after its fourth-quarter results announcement as geopolitical tensions depressed stock markets again.
Scrip - January 26, 2026
Despite group sales growth and its pharmaceutical division revenue weathering a big loss of exclusivity, J&J experienced stock price weakness after its fourth-quarter results announcement as geopolitical tensions depressed stock markets again.
Scrip - January 26, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: J&J’s oncology prospects; GSK’s Rapt deal; 2026’s biggest expected launches; optimistic financial outlook at JPM; and Scrip Asks about the competitive dynamics landscape.
Scrip - January 26, 2026
In this week's episode: J&J’s oncology prospects; GSK’s Rapt deal; 2026’s biggest expected launches; optimistic financial outlook at JPM; and Scrip Asks about the competitive dynamics landscape.
Scrip - January 26, 2026
Cipla Tackles Lanreotide Supply Woes, Solidifies India Diabetes Position
Lanreotide supply issues cloud Cipla’s Q3 FY26 earnings, with impact seen in Q4 as well, though pipeline assets augur well for US growth continuity. Perpetual rights to Novartis’s Galvus effective Jan 1, seen adding momentum to India diabetes gains.
Scrip - January 26, 2026
Lanreotide supply issues cloud Cipla’s Q3 FY26 earnings, with impact seen in Q4 as well, though pipeline assets augur well for US growth continuity. Perpetual rights to Novartis’s Galvus effective Jan 1, seen adding momentum to India diabetes gains.
Scrip - January 26, 2026
QMSR Countdown: FDA Provides Last-Minute Tips On New Regs With Compliance Deadline Just Days Away
As the deadline for the US FDA’s new quality system incorporating international standards fast approaches, the agency held a town hall to offer industry some last-minute tips to get ready for the regulatory framework.
Medtech Insight - January 26, 2026
As the deadline for the US FDA’s new quality system incorporating international standards fast approaches, the agency held a town hall to offer industry some last-minute tips to get ready for the regulatory framework.
Medtech Insight - January 26, 2026
Mechanics, Not Microchips: How Simplified Design Could Help Medical Devices Reach More Patients
In an era of AI and other advanced computing methods, pure-play mechanical devices could offer better pricing and practicality, according to the CEO of prosthetics company Metacarpal.
Medtech Insight - January 26, 2026
In an era of AI and other advanced computing methods, pure-play mechanical devices could offer better pricing and practicality, according to the CEO of prosthetics company Metacarpal.
Medtech Insight - January 26, 2026
Growth Drug In Infant Supplements Adds To US Regulators’ Children’s Health Product Concerns
When FDA warned Agebox about selling iKids-Growth IGF-1 Support supplements as unapproved drugs, agency along with CDC had for around a month been investigating outbreak of infant botulism linked to ByHeart formula.
HBW Insight - January 27, 2026
When FDA warned Agebox about selling iKids-Growth IGF-1 Support supplements as unapproved drugs, agency along with CDC had for around a month been investigating outbreak of infant botulism linked to ByHeart formula.
HBW Insight - January 27, 2026
Lupin Signs A Semaglutide Licensing Agreement With Galenicum For 23 Markets
In line with previously disclosed launch and partnering plans for GLP-1 products, Lupin shook hands with Galenicum, securing commercial rights to injectable semaglutide.
Generics Bulletin - January 26, 2026
In line with previously disclosed launch and partnering plans for GLP-1 products, Lupin shook hands with Galenicum, securing commercial rights to injectable semaglutide.
Generics Bulletin - January 26, 2026
J.P. Morgan: ANI Targets Rare Disease Pivot As Cortrophin Drives Company Past $1bn Revenue Mark
ANI’s Cortrophin Gel is benefiting from significant under-penetration in areas such as nephrology, neurology, rheumatology and pulmonology, the firm told attendees to the recent J.P. Morgan Healthcare Conference.
Generics Bulletin - January 26, 2026
ANI’s Cortrophin Gel is benefiting from significant under-penetration in areas such as nephrology, neurology, rheumatology and pulmonology, the firm told attendees to the recent J.P. Morgan Healthcare Conference.
Generics Bulletin - January 26, 2026
Dr Reddy’s Sets Out Timelines For Orencia Biosimilar
As Dr Reddy’s delivered results for its financial third quarter, the firm revealed a slew of updates for key biosimilars in its pipeline including filing and launch plans for abatacept in the US and Europe, as well as US setbacks on rituximab and denosumab.
Generics Bulletin - January 26, 2026
As Dr Reddy’s delivered results for its financial third quarter, the firm revealed a slew of updates for key biosimilars in its pipeline including filing and launch plans for abatacept in the US and Europe, as well as US setbacks on rituximab and denosumab.
Generics Bulletin - January 26, 2026
2026: EU MDR Review Will Give Europe Back Its Medtech Relevance
The medtech industry has been disrupted by tariffs and China’s volume-based procurement policies. While India is expected to emerge as a key long-term growth market, near-term upside may come from a potential rebound in EU attractiveness following the MDR reform proposals in December 2025.
In Vivo - January 26, 2026
The medtech industry has been disrupted by tariffs and China’s volume-based procurement policies. While India is expected to emerge as a key long-term growth market, near-term upside may come from a potential rebound in EU attractiveness following the MDR reform proposals in December 2025.
In Vivo - January 26, 2026
Beyond Viagra: How Dicot’s Novel Mechanism Could Reshape The $5bn ED Market
The Swedish biotech's LIB-01 offers eight-week efficacy from three-day dosing, targeting high discontinuation rates with current PDE5 inhibitors.
In Vivo - January 26, 2026
The Swedish biotech's LIB-01 offers eight-week efficacy from three-day dosing, targeting high discontinuation rates with current PDE5 inhibitors.
In Vivo - January 26, 2026
Fred Hassan Talks Pharma Investment Trends, Key Drivers And AI
The pharma titan candidly speaks about the M&A landscape, high R&D costs and the potential of AI as the industry gets set to navigate a host of existing and new challenges.
In Vivo - January 26, 2026
The pharma titan candidly speaks about the M&A landscape, high R&D costs and the potential of AI as the industry gets set to navigate a host of existing and new challenges.
In Vivo - January 26, 2026